Drug tolerance and minimal residual disease (MRD) are likely to prelude acquired resistance to targeted therapy. Mechanisms that allow persister cells to survive in the presence of targeted therapy are being characterized but selective vulnerabilities for these subpopulations remain uncertain. We identified cellular inhibitor of apoptosis protein 2 (cIAP2) as being highly expressed in SOX10-deficient drug tolerant persister (DTP) melanoma cells. Here, we show that cIAP2 is sufficient to induce tolerance to MEK inhibitors, likely by decreasing the levels of cell death. Mechanistically, cIAP2 is upregulated at the transcript level in SOX10-deficient cells and the AP-1 complex protein, JUND, is required for its expression. Using a patient-derived xenograft model, we demonstrate that treatment with the cIAP1/2 inhibitor, birinapant, during the MRD phase delays the onset of resistance to BRAF inhibitor and MEK inhibitor combination therapy. Together, our data suggest that cIAP2 upregulation in SOX10-deficient subpopulations of melanoma cells induces drug tolerance to MAPK targeting agents and provides a rationale to test a novel therapeutical approach to target MRD.
Pubmed ID: 37343247 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This unknown targets Goat Rabbit IgG H & L Chain Specific Peroxidase Conjugate
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis monoclonal targets cyclin A (B-8)
View all literature mentionsThis monoclonal targets Sox9
View all literature mentionsThis polyclonal targets NF- B1 p105/p50
View all literature mentionsThis monoclonal targets WNT5A
View all literature mentionsThis monoclonal targets p21 Waf1/Cip1
View all literature mentionsThis polyclonal targets Phospho-Rb (Ser807/811)
View all literature mentionsThis monoclonal targets Hsp90aa1
View all literature mentionsThis monoclonal targets c-IAP2
View all literature mentionsThis polyclonal targets NFkappaB p65 (A)
View all literature mentionsThis recombinant monoclonal targets Fibronectin
View all literature mentionsThis monoclonal targets c-IAP1
View all literature mentionsThis monoclonal targets V5-Tag
View all literature mentionsThis polyclonal targets Actin
View all literature mentionsThis monoclonal targets DFNA5/GSDME
View all literature mentionsThis monoclonal targets Casp3
View all literature mentionsThis polyclonal targets Cleaved PARP (Asp214) (Human Specific)
View all literature mentionsThis polyclonal targets p44/42 MAPK (Erk1/2)
View all literature mentionsView all literature mentions
This monoclonal targets Sox9
View all literature mentionsThis monoclonal targets WNT5A
View all literature mentionsThis monoclonal targets Hsp90aa1
View all literature mentionsThis monoclonal targets DFNA5/GSDME
View all literature mentionsThis monoclonal targets DFNA5/GSDME
View all literature mentionsView all literature mentions
This unknown targets Goat Rabbit IgG H & L Chain Specific Peroxidase Conjugate
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsView all literature mentions
This monoclonal targets cyclin A (B-8)
View all literature mentionsThis unknown targets Goat Rabbit IgG H & L Chain Specific Peroxidase Conjugate
View all literature mentionsThis polyclonal targets NFkappaB p65 (A)
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal targets Actin
View all literature mentionsThis monoclonal targets cyclin A (B-8)
View all literature mentionsThis polyclonal targets NFkappaB p65 (A)
View all literature mentionsThis recombinant monoclonal targets Fibronectin
View all literature mentionsThis polyclonal targets Actin
View all literature mentionsThis monoclonal targets Casp3
View all literature mentionsThis recombinant monoclonal targets Fibronectin
View all literature mentionsThis polyclonal targets NF- B1 p105/p50
View all literature mentionsThis monoclonal targets Casp3
View all literature mentionsThis monoclonal targets p21 Waf1/Cip1
View all literature mentionsThis polyclonal targets NF- B1 p105/p50
View all literature mentionsThis monoclonal targets c-IAP1
View all literature mentionsThis polyclonal targets Cleaved PARP (Asp214) (Human Specific)
View all literature mentionsThis monoclonal targets p21 Waf1/Cip1
View all literature mentionsThis monoclonal targets c-IAP1
View all literature mentionsThis polyclonal targets p44/42 MAPK (Erk1/2)
View all literature mentionsThis polyclonal targets Cleaved PARP (Asp214) (Human Specific)
View all literature mentionsThis polyclonal targets p44/42 MAPK (Erk1/2)
View all literature mentionsThis polyclonal targets Phospho-Rb (Ser807/811)
View all literature mentionsThis monoclonal targets V5-Tag
View all literature mentionsThis monoclonal targets c-IAP2
View all literature mentions